Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 1 3Phase 1/2 2

Status

Completed 11Recruiting 3Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × capivasertib × Clear all
NCT03616587 2026-04-30

SERENA-1

AstraZeneca

Phase 1 Active not recruiting
396 enrolled
Breast

Breast Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

AstraZeneca

Phase 1 Active not recruiting
138 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡